2024 Summer Conference Onsite Guide by American Academy of Neurology

MEETING TIPS

Quick Links

For handy access to most of the links mentioned below and to download your certificate of attendance, visit AAN.com/SCQuickLinks

WiFi

WiFi is available throughout the conference.

Network: AAN 2024

Password: neurology

AAN Conferences Mobile App and Online Platform

Download the AAN Conferences mobile app for the most accurate, up-tothe-minute information. Enjoy a seamless experience between the mobile app and online platform, which also allow you to revisit past sessions.

Conference attendees have access to content through August 5, 2024. Visit AAN.com/SCOnline and use your 6-digit ID and password to log in to the online platform or view content on the AAN Conferences mobile app. It may take up to 48 hours after session completion for content to become available.

Audience Response

To participate in audience response, visit AAN.cnf.io or connect via the main menu of the AAN Conferences mobile app.

Program Slides

Slides are available online at AAN.com/Materials or through the online platform or AAN Conferences mobile app. You can access program materials through May 1, 2025. (Please note that availability of materials is at the discretion of the specific speaker. Not all sessions will have materials.)

MEETING TIPS

Claiming CME Credits

Complete your evaluations to get your CME credits by August 5, 2024 (or May 1, 2025, with Summer Conference On Demand) by using the AAN Conferences mobile app or by visiting AAN.com/CME. Transcripts will be available upon evaluation submission. AAN members can also access their transcript via NeuroTracker™ at AAN.com/NeuroTracker

Lactation and Prayer Rooms

Private rooms for nursing, pumping, and/or praying are available for use during the conference. Visit registration for access.

Meals and Coffee Breaks

A light breakfast will be provided daily 30 minutes before the start of the first course. Lunch and coffee break times and locations are noted in the schedule.

Want More Time to Review Programs?

Add Summer Conference On Demand to your registration to extend your access to session recordings through May 1, 2025. Check the back of your badge to see if you already have Summer Conference On Demand. If not, head to registration or email aanscsupport@cmrus.com by August 5, 2024, to purchase and save up to 55%.

Meeting Policies

Complete meeting policies are posted at AAN.com/ConfGuidelines

SCAN ME

MEETING TIPS

ACCME Accreditation

The American Academy of Neurology Institute (AANI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation

American Academy of Neurology Institute (AANI), a subsidiary of the AAN, designates this live activity for a maximum of 29 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPN Statement

The American Board of Psychiatry and Neurology (ABPN) has reviewed the 2024 AAN Summer Conference and has approved the program as a part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of continuing certification.

Exhibit Hall

Attend the Poster and Exhibit Hall Break on Friday to network with colleagues and make new connections!

Learn about the latest advancements in products and services enhancing the lives of autoimmune neurology patients and their care providers.

Complete your exhibit hall passport by visiting the participating booths and be entered into a drawing to win prizes, including a 2024 Fall Conference registration!

MEETING-AT-A-GLANCE

FRIDAY,

JULY 19

8:00 a.m.–10:10 a.m.

C1 Autoimmune Neurology Updates

10:10 a.m.–10:25 a.m. Break

10:25 a.m.–11:25 a.m.

C2 Neural Antibodies: From Discovery to Clinical Testing

12:00 p.m.–12: 45 p.m.

Career Mentoring and Networking: Education

1:00 p.m.–2:35 p.m.

12:00 p.m.–12: 45 p.m.

Career Mentoring and Networking: Translational Science

C3 Essential Immunology Principles for the (Autoimmune) Neurologist

2:30 p.m.–3:45 p.m. Exhibit and Poster Hall Break

11:15 a.m.–1:15 p.m. Exhibit and Poster Hall Lunch

12:00 p.m.–12: 45 p.m.

Career Mentoring and Networking: Clinical/ Multicenter Trial

1:00 p.m.–2:35 p.m.

C4 Models of Infection as a Trigger for Autoimmunity

12:00 p.m.–1:00 p.m. Poster Session 1

1:00 p.m.–2:35 p.m.

C5 Peripheral Nervous System Autoimmunity

2:45 p.m.–3:45 p.m. Poster Session 2

3:45 p.m.–4:30 p.m.

C6 Opening Keynote: Central Nervous System and Immune System Interactions: The Role of CNS Lymphatics

4:30 p.m.–6:30 p.m.

C7 Case Studies

5:30 p.m.–6:30 p.m.

Industry Therapeutic Update from Cartesian Therapeutics

8:00 a.m.

8:00 a.m.–9:35 a.m.

C8 Clinical and Treatment Approach to Meningitis

9:00 a.m.

SATURDAY, JULY 20

8:00 a.m.–9:35 a.m.

C9 Cancer-associated Neurological Autoimmunity

10:00 a.m.

9:35 a.m.–9:50 a.m. Break

9:50 a.m.–11:25 a.m.

C11 Central Nervous System Space-occupying Lesions

11:00 a.m.

11:15 a.m.–1:15 p.m.

Exhibit and Poster Hall Lunch

12:00 p.m.

1:00 p.m.

1:20 p.m.–2:55 p.m.

C14 Neuroinfectious Disease Diagnostics

9:50 a.m.–11:25 a.m.

C12 Autoimmune Movement Disorders

8:00 a.m.–9:35 a.m.

C10 Genetics and Neurological Autoimmunity

12:15 p.m.–1:15 p.m.

Industry Therapeutic Update from argenx

9:50 a.m.–11:25 a.m.

C13 Neuromyelitis Optica and MOG-antibody Associated Disease Diagnosis and Treatment

12:00 p.m.–1:00 p.m. Poster Session 3

1:20 p.m.–2:55 p.m.

2:00 p.m.

3:00 p.m.

2:55 p.m.–3:10 p.m. Break

3:10 p.m.–4:45 p.m.

C17 Neuro-infections in Immunocompromised

4:00 p.m.

5:00 p.m.

4:45 p.m.–5:30 p.m.

C15 Suspecting Autoimmune Encephalitis: And Now What?

C16 Clinical Approach to Myelopathy

3:10 p.m.–4:45 p.m.

C18 Measuring and Changing Outcomes in Autoimmune Encephalitis

3:10 p.m.–4:45 p.m.

C19 Monitoring Necessities for Immunotherapy Prescribers

C20 Closing Keynote: Paraneoplastic Neurological Diseases: What’s Next

6:00 p.m.

8:00 a.m.–10:10 a.m.

C1: Autoimmune Neurology Updates 2

Location: Salon

This program is supported in part by an educational grant from UCB, Inc.

Learning Objectives: Participants should become familiar with recent advances in autoimmune encephalitis, neuromyelitis optica, MOG antibody associated disease, pediatric neurological autoimmune disorders, and clinical trials in autoimmune neurology.

Moderators:

Stacey Clardy, MD, PhD, FAAN, Salt Lake City, UT

Brenda Banwell, MD, FAAN, Philadelphia, PA

Lecture/Faculty:

8:00 a.m.–8:10 a.m.

» Welcome

Stacey Clardy, MD, PhD, FAAN, Salt Lake City, UT

Anastasia Zekeridou, MD, PhD, Rochester, MN

8:10 a.m.–8:40 a.m.

» Autoimmune Encephalitis Update

Sarosh R. Irani, MD, PhD, FRCP, FEAN, Jacksonville, FL

8:40 a.m.–9:10 a.m.

» MOGAD-NMO Update

Eoin P. Flanagan, MBBCh, FAAN, Rochester, MN

9:10 a.m.–9:40 a.m.

» Autoimmune Neurology Update – Pediatrics

Jennifer Graves, MD, PhD, San Diego, CA

9:40 a.m.–10:10 a.m.

» Neuroinfectious Disease Updates

Kiran Thakur, MD, FAAN, New York, NY

10:10 a.m.–10:25 a.m.

Break

Location: Salon Pre-function

10:25 a.m.–11:25 a.m.

C2 : Neural Antibodies: From Discovery to Clinical Testing 1

Location: Salon

Learning Objectives: Participants should become familiar with the techniques used to discover the antigenic targets of antibodies, how to validate them for clinical practice, and red flags for antibody testing and interpretation.

Moderators:

Angela Vincent, MBBS, MSc, Oxford, United Kingom

Anastasia Zekeridou, MD, PhD, Rochester, MN

Lecture/Faculty:

10:25 a.m.–10:55 a.m.

» Antibody Discovery Principles and Methodologies

Michael R. Wilson, MD, FAAN, San Francisco, CA

10:55 a.m.–11:25 a.m.

» Antibody Validation, Clinical Utility, and Caveats: Are All Antibodies Useful?

Andrew McKeon, MD, Rochester, MN

11:15 a.m.–1:15 p.m.

Exhibit and Poster Hall Lunch

Location: Grand Ballroom

12:00 p.m.–12:45 p.m.

Career Mentoring and Networking: Education

Location: 212-214

Learning Objectives: Participants should gain practical guidance from experienced neurologists on how to develop and navigate distinct career paths within the rapidly growing fields of autoimmune neurology and neuroinfectious diseases.

Moderators:

Erin Longbrake, MD, PhD, FAAN, New Haven, CT

Jeffrey M. Gelfand, MD, MAS, FAAN, San Francisco, CA

Lecture/Faculty:

12:00 p.m.–12:45 p.m.

» Career Mentoring and Networking: Education

Eoin P. Flanagan, MBBCh, FAAN, Rochester, MN

Amanda L. Piquet, MD, FAAN, Aurora, CO

Kyle M. Blackburn, MD, Dallas, TX

Kiran Thakur, MD, FAAN, New York, NY

SCHEDULE FRIDAY, JULY 19

12:00 p.m.–12:45 p.m.

Career Mentoring and Networking: Translational Science

Location: 204-207

Moderators:

Amy Kunchok, MBBS, Cleveland, OH

Eric Lancaster, MD, PhD, Philadelphia, PA

Lecture/Faculty:

12:00 p.m.–12:45 p.m.

» Career Mentoring and Networking: Translational Science

Sarosh R. Irani, MD, PhD, FRCP, FEAN, Jacksonville, FL

Jenny Linnoila, MD, PhD, Pittsburgh, PA

Marianna Spatola, MD, PhD, Barcelona, Spain

Emmanuel Mignot, MD, PhD, Palo Alto, CA

ENCEPHALITIS

2ND & 3RD DECEMBER

12:00 p.m.–12:45 p.m.

Career Mentoring and Networking: Clinical/Multicenter Trials

Location: Salon

Moderators:

Arun Venkatesan, MD, PhD, Baltimore, MD

Grace Gombolay, MD, Atlanta, GA

Lecture/Faculty:

12:00 p.m.–12:45 p.m.

» Career Mentoring and Networking: Clinical/ Multicenter Trials

Marinos C. Dalakas, MD, FAAN, Philadelphia, PA

Sean J. Pittock, MD, Rochester, MN

David B. Clifford, MD, FAAN, Saint Louis, MO

Michael Levy, MD, PhD, FAAN, Boston, MA

Brenda Banwell, MD, FAAN, Philadelphia, PA

UCSF Weill Institute for Neurosciences, USA

AVA EASTON

International, UK

KEYNOTE & GUEST SPEAKERS

PROF. MICHAEL WILSON

DR. BHAGTESHWAR SINGH

University of Liverpool & Royal Liverpool University Hospital, UK

DR.

Encephalitis

University of Barcelona and La Caixa Research Institute, Spain

DR. MARIANNA SPATOLA

12:00 p.m.–1:00 p.m.

P1: Poster Session 1

Location: Grand Ballroom

Learning Objectives: Participants will review the latest research on autoimmune neurology. Posters are available in-person or online.

1:00 p.m.–2:35 p.m.

C3 : Essential Immunology Principles for the (Autoimmune) Neurologist 1.5

Location: 204-207

Learning Objectives: Participants should become familiar with basic immunological principles that are useful in clinical practice.

Moderators:

Avi Gadoth, MD, Tel-Aviv, Israel

Sudarshini Ramanathan, MBBS, PhD, FRACP, Sydney, NSW, Australia

Lecture/Faculty:

1:00 p.m.–1:27 p.m.

» Targeting B-cells and Antibodies

Sarosh R. Irani, MD, PhD, FRCP, FEAN, Jacksonville, FL

1:27 p.m.–1:54 p.m.

» T-cells: As Therapeutic Targets and Overzealous Attackers

Frank Leypoldt, Kiel, Germany

1:54 p.m.–2:21 p.m.

» Major Histocompatibility Complex Basics: What Is It, Why Do We Care?

Emmanuel Mignot, MD, PhD, Palo Alto, CA

2:21 p.m.–2:28 p.m.

» Permissive Central Tolerance Plus Defective Peripheral Checkpoints License Pathogenic Memory B cells in CASPR2-Antibody Encephalitis

Anna L. Harrison

2:28 p.m.–2:35 p.m.

» Peripherally Administered Therapeutic One-armed Antibody Reversed Behavioral Abnormalities in a Marmoset Model of AntiNMDAR Encephalitis

Mitsuyuki Matsumoto, PhD

1:00 p.m.–2:35 p.m.

C4 : Models of Infection as a Trigger for Autoimmunity 1.5

Location: Salon

Learning Objectives: Participants should become familiar with the mechanisms underlying post-infectious neurological autoimmunity and their clinical manifestations.

Moderators:

Maarten J. Titulaer, MD, PhD, Rotterdam, Netherlands

Alexander J. Gill, MD, PhD, Baltimore, MD

Lecture/Faculty:

1:00 p.m.–1:27 p.m.

» Post-infectious Neurological Autoimmunity in the Clinic

Thais Armangue, MD, Barcelona, Spain

1:27 p.m.–1:54 p.m.

» Experimental Models of Post-infectious CNS Neurological Autoimmunity

Marianna Spatola, MD, PhD, Barcelona, Spain 1:54 p.m.–2:21 p.m.

» Virus-like Capsids That Trigger Paraneoplastic Neurological Symptoms

Jason Shepherd, Salt Lake City, UT

2:21 p.m.–2:28 p.m.

» Powassan Virus Encephalitis in Pediatric Patients: A Case Series

Celia Greenlaw, MD

2:28 p.m.–2:35 p.m.

» FACE DROP: A Clinical Risk Assessment Tool to Differentiate Acute Lyme Disease Facial Palsy From Bell’s Palsy

Caleb R. McEntire, MD

SCHEDULE

1:00 p.m.–2:35 p.m.

C5 : Peripheral Nervous System

Autoimmunity

Location: 212-214

This program is supported in part by an educational grant from argenx US Inc.

FRIDAY, JULY 19

3:45 p.m.–4:30 p.m.

C6 : Opening Keynote

1.5

Learning Objectives: Participants should become familiar with diagnosis and treatment of peripheral nervous system autoimmune disorders.

Moderators:

Bob Bucelli, MD, PhD, Saint Louis, MO

Mayra Montalvo Perero, MD, Gainesville, FL

Lecture/Faculty:

1:00 p.m.–1:27 p.m.

» Clinical Approach to Immune Mediated Neuropathies

Eric Lancaster, MD, PhD, Philadelphia, PA

1:27 p.m.–1:54 p.m.

» Navigating the Spectrum of Neural Specific Antibodies in Autoimmune Neuropathies

Divyanshu Dubey, MD, FAAN, Rochester, MN

1:54 p.m.–2:21 p.m.

» Inflammatory Myopathies

Lisa Christopher-Stine, Baltimore, MD

2:21 p.m.–2:28 p.m.

» Efficacy and Safety of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy: Results of ADHERE/ADHERE+

Niraja S. Suresh, MD

2:28 p.m.–2:35 p.m.

» Long-term Corticosteroid Treatment Patterns and Steroid-sparing Effects of Approved Treatments for Generalized Myasthenia Gravis in the United States

Christopher A. Scheiner, MD, PhD

2:30 p.m.–3:45 p.m.

Exhibit and Poster Hall Break

SCHEDULE

8:00 a.m.–9:35 a.m.

C8 : Clinical and Treatment Approach to Meningitis 1.5

Location: 204-207

Learning Objectives: Participants should become familiar with a diagnostic and treatment approach to meningitis.

Moderators:

Arun Venkatesan, MD, PhD, Baltimore, MD

Masoud Majed, MD, Los Angeles, CA

Lecture/Faculty:

8:00 a.m.–8:27 a.m.

» Inflammatory Etiologies

Amanda L. Piquet, MD, FAAN, Aurora, CO

8:27 a.m.–8:54 a.m.

» Infectious Etiologies of Meningitis

Allen J. Aksamit, Jr., MD, FAAN, Rochester, MN

8:54 a.m.–9:21 a.m.

» Cases

Jeffrey M. Gelfand, MD, MAS, FAAN, San Francisco, CA

9:21 a.m.–9:28 a.m.

» Trends in Clinico-Radiological and Laboratory Characteristics of All-cause Meningoencephalitis in Western Rajasthan

Krishna Kanth Ravi, PhD

9:28 a.m.–9:35 a.m.

» Neurological Manifestations of Leptospirosis: A Retrospective Study from India

Bhavya Jaya Venugopal

SATURDAY, JULY 20

8:00 a.m.–9:35 a.m.

C9 : Cancer-associated Neurological Autoimmunity 1.5

Location: Salon

Learning Objectives: Participants should be able to diagnose and treat paraneoplastic neurological diseases as well as neurological complications of immune checkpoint inhibitor and CAR-T cell cancer immunotherapy.

Moderators:

Hesham A. Abboud, MD, Cleveland, OH

Smathorn Thakolwiboon, MD, La Crosse, WI

Lecture/Faculty:

8:00 a.m.–8:27 a.m.

» Paraneoplastic Neurological Syndromes

Jerome Honnorat, MD, PhD, Lyon, France

8:27 a.m.–8:54 a.m.

» Complications of Immune Checkpoint Inhibitor Cancer Immunotherapy

Cristina Valencia Sanchez, MD, Scottsdale, AZ

8:54 a.m.–9:21 a.m.

» CAR-T Cell Related Neurological Toxicity

Bianca Santomasso, MD, New York, NY

9:21 a.m.–9:28 a.m.

» ANNA1 Neurological Autoimmunity: A Comparative Analysis of Cancers, Neurological Phenotype and Coexisting Antibodies Across Age Demographics

Naveen K. Paramasivan, MD

9:28 a.m.–9:35 a.m.

» Neurologic Outcomes in People with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder Exposed To Immune Checkpoint Inhibitors

Alexander J. Gill, MD, PhD

Information is accurate as of June 28, 2024, and is subject to change.

8:00 a.m.–9:35 a.m.

C10 : Genetics and Neurological Autoimmunity

Location: 212-214

1.5

Learning Objectives: Participants should become familiar with genetic diseases manifesting mimicking neurological autoimmunity and how to diagnose them.

Moderators:

Grace Gombolay, MD, Atlanta, GA

Avindra Nath, MD, MBBS, FAAN, Bethesda, MD

Lecture/Faculty:

8:00 a.m.–8:27 a.m.

» Inborn Errors of Immunity Affecting the Nervous System

Ariane Soldatos, MD, FAAN, Bethesda, MD

8:27 a.m.–8:54 a.m.

» Genetic Leukodystrophies Mimicking CNS Inflammation

Jennifer L. Orthmann Murphy, MD, PhD, Philadelphia, PA

8:54 a.m.–9:21 a.m.

» Approach to Genetic Testing

Magdalena Walkiewicz, Bethesda, MD

9:21 a.m.–9:28 a.m.

» Erdheim-Chester Disease Masquerading as CLIPPERS

Samir Alkabie, MD, MSc

9:28 a.m.–9:35 a.m.

» Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Patient with Noonan Syndrome and Prior Juvenile Myelomonocytic Leukemia

Madeleine Hebert, MD

9:35 a.m.–9:50 a.m.

Break

Location: Salon Pre-function

9:50 a.m.–11:25 a.m.

C11: Central Nervous System

Space-occupying Lesions 1.5

Location: 204-207

Learning Objectives: Participants should become familiar with the differential diagnosis and approach to central nervous system spaceoccupying lesions.

Moderators:

Tracey Cho, MD, FAAN, Iowa City, IA

Spencer Hutto, MD, Atlanta, GA

Lecture/Faculty:

9:50 a.m.–10:17 a.m.

» Inflammatory Etiologies

W. O. Tobin, PhD, MBBCh, BAO, FAAN, Rochester, MN

10:17 a.m.–10:44 a.m.

» Infectious Etiologies

Kiran Thakur, MD, FAAN, New York, NY 10:44 a.m.–11:11 a.m.

» Cases

Shamik Bhattacharyya, MD, FAAN, Boston, MA 11:11 a.m.–11:18 a.m.

» Association Between Radiographic Features of Hypertrophic Pachymeningitis and its Underlying Diagnoses

Jiyeon Son, MD 11:18 a.m.–11:25 a.m.

» Efficacy Analysis of Therapeutic Regimens for Neurocysticercosis: Insights from a Network Meta-Analysis

Suhrud Panchawagh

SCHEDULE

9:50 a.m.–11:25 a.m.

C12 : Autoimmune Movement Disorders 1.5

Location: Salon

Learning Objectives: Participants should become familiar with the clinical presentation, diagnosis, and treatment of autoimmune movement disorders, including cerebellar ataxia, stiff-person syndrome, and hyperkinetic movement disorders.

Moderators:

Andrew McKeon, MD, Rochester, MN

Yujie Wang, MD, Seattle, WA

Lecture/Faculty:

9:50 a.m.–10:17 a.m.

» Autoimmune Cerebellar Ataxias

Jenny Linnoila, MD, PhD, Pittsburgh, PA 10:17 a.m.–10:44 a.m.

» Stiff Person Spectrum Disorders

Marinos C. Dalakas, MD, FAAN, Philadelphia, PA 10:44 a.m.–11:11 a.m.

» Hyperkinetic Movement Disorders

Bettina Balint, MD, Zurich, Switzerland

11:11 a.m.–11:18 a.m.

» Not One-in-a-million: A Single-Center Case Series of Patients with Stiff Person Syndrome

Paul D. Crane, MD 11:18 a.m.–11:25 a.m.

» Characterize GAD65-specific T cell Responses in Patients with Stiff-Person Syndrome and Type-I Diabetes.

Pei Shang, MD, PhD

SATURDAY, JULY 20

9:50 a.m.–11:25 a.m.

C13 : Neuromyelitis Optica and MOG-antibody Associated Disease Diagnosis and Treatment 1.5

Location: 212-214

This program is supported in part by an educational grant from UCB, Inc.

Learning Objectives: Participants should become familiar with the clinical presentation, serological diagnosis, and treatment of NMOSD and MOGAD

Moderators:

Brenda Banwell, MD, FAAN, Philadelphia, PA

Duriel I. Hardy, MD, Austin, TX

Lecture/Faculty:

9:50 a.m.–10:17 a.m.

» Neuromyelitis Optica Clinical Manifestations and Treatment Approach

Dalia Rotstein, MD, North York, ON, Canada 10:17 a.m.–10:44 a.m.

» MOGAD Clinical Manifestations and Treatment Approach

Sudarshini Ramanathan, MBBS, PhD, FRACP, Sydney, NSW, Australia

10:44 a.m.–11:11 a.m.

» Pitfalls in Serological Diagnosis and Biomarkers of Glial and Neural Damage in MOGAD and NMOSD

Sara Mariotto, MD, PhD, Verona, Italy

11:11 a.m.–11:18 a.m.

» Pediatric MOGAD: Clinical Experience in a Tertiary Care Setting

Karla Salazar, MD

11:18 a.m.–11:25 a.m.

» Cerebellar Involvement During Attacks of Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder

Alessandro Dinoto, MD

11:15 a.m.–1:15 p.m.

Exhibit and Poster Hall Lunch

Location: Grand Ballroom

Information is accurate as of June 28, 2024, and is subject to change.

11:30 a.m.–12:15 p.m.

Summer Conference Patient

Presentation Stage

SCHEDULE

1:20 p.m.–2:55 p.m.

C14 : Neuroinfectious Disease Diagnostics 1.5

Location: 204-207

Learning Objectives: Participants should be able to choose and interpret appropriate diagnostic testing when suspecting a neuroinfectious disease.

Moderators:

Farrah J. Mateen, MD, PhD, FAAN, Boston, MA

Michael R. Wilson, MD, FAAN, San Francisco, CA

Lecture/Faculty:

1:20 p.m.–1:47 p.m.

» Overview of Diagnostic Modalities

Prashanth S. Ramachandran, Jr., MBBS, Melbourne, VIC, Australia

1:47 p.m.–2:14 p.m.

» Pitfalls of Diagnostic Testing: When the Results Do Not Make Sense

Michel Toledano, MD, Rochester, MN

2:14 p.m.–2:41 p.m.

» Cases Felicia Chow, MD, San Francisco, CA

2:41 p.m.–2:48 p.m.

» CSF Metagenomics and Host Transcriptomics of Cryptogenic New-onset Refractory Status Epilepticus

Mary Karalius, MD

2:48 p.m.–2:55 p.m.

» Cryptococcal Meningitis in HIV: A Comparative Study Between Asymptomatic and Symptomatic Cases and Mortality Parameters

Bhavya Jaya Venugopal

SATURDAY, JULY 20

1:20 p.m.–2:55 p.m.

C15 : Suspecting Autoimmune Encephalitis: And Now What? 1.5

Location: Salon

Learning Objectives: Participants should recognize clinical presentations and diagnostic modalities for autoimmune and infectious encephalitides, as well as treatment approaches. Moderators:

Melissa A. Wright, MD, Salt Lake City, UT

Sean J. Pittock, MD, Rochester, MN

Lecture/Faculty:

1:20 p.m.–1:47 p.m.

» Autoimmune Encephalitis Diagnosis and Misdiagnosis

Amy Kunchok, MBBS, Cleveland, OH

1:47 p.m.–2:14 p.m.

» Approach to Infectious Encephalitides

Nicholas Davies, London, United Kingdom

2:14 p.m.–2:41 p.m.

» Treatment Approach in Autoimmune Encephalitis

Tammy L. Smith, MD, PhD, Salt Lake City, UT

2:41 p.m.–2:48 p.m.

» MRI Characteristics of LGI1- and CASPR2Antibody Encephalitis: Independent Discovery and Validation Cohorts

Mark J. Kelly, MBBS

2:48 p.m.–2:55 p.m.

» Intrathecal Steroids: A More Targeted Approach to Central Nervous System Inflammation

Kristen Fisher, DO

Information is accurate as of June 28, 2024, and is subject to change.

1:20 p.m.–2:55 p.m.

C16: Clinical Approach to Myelopathy 1.5

Location: 212-214

Learning Objectives: Participants should become familiar with how to diagnose and recognize mimics of autoimmune and infectious myelopathies.

Moderators:

Shailee S. Shah, MD, Nashville, TN

Eoin P. Flanagan, MBBCh, FAAN, Rochester, MN

Lecture/Faculty:

1:20 p.m.–1:47 p.m.

» Autoimmune/Inflammatory Myelopathies

Alfonso S. Lopez, MD, Jacksonville, FL

1:47 p.m.–2:14 p.m.

» Infectious Myelopathies

Tracey Cho, MD, FAAN, Iowa City, IA

2:14 p.m.–2:41 p.m.

» Inflammatory Myelopathy Mimics

Kyle M. Blackburn, MD, Dallas, TX

2:41 p.m.–2:48 p.m.

» Comparison of MRI Brain and Spine Lesions During Clinical Attacks and Remission in MOG Antibody-associated Disease and Multiple Sclerosis

Stephanie Syc-Mazurek, MD, PhD

2:48 p.m.–2:55 p.m.

» Utility of Flexion-extension MRI to Reveal Occult Cervical Spondylotic Compression in Those with Suspected Inflammatory or Undifferentiated Myelopathies

Santiago Martinez Sosa, MBBS

2:55 p.m.–3:10 p.m.

Break

Location: Salon Pre-function

3:10 p.m.–4:45 p.m.

C17: Neuro-infections in Immunocompromised 1.5

Location: 204-207

Learning Objectives: Participants should become familiar with the neurological infectious complications of immunocompromised patients.

Moderators:

Kiran Thakur, MD, FAAN, New York, NY

Nicholas Davies, London, United Kingdom

Lecture/Faculty:

3:10 p.m.–3:37 p.m.

» HIV-related Complications of the Nervous System

Avindra Nath, MD, MBBS, FAAN, Bethesda, MD

3:37 p.m.–4:04 p.m.

» Infections Related to Iatrogenic Immunosuppression

David B. Clifford, MD, FAAN, Saint Louis, MO

4:04 p.m.–4:31 p.m.

» Cases

David R. Renner, MD, FAAN, Salt Lake City, UT

4:31 p.m.–4:38 p.m.

» Unveiling the Spectrum: Investigating HIV-Associated Neurological Challenges in Hospitalized Patients and Predicting Prognosis Over Three Months

Mamadou Diallo, MD

4:38 p.m.–4:45 p.m.

» Comparative Efficacy of Adjuvant Rifampicin, Levofloxacin, and Their Combination in Tuberculous Meningitis With and Without HIV Co-infection: A Systematic Review and Meta-Analysis

Nathania Nathania

SCHEDULE

3:10 p.m.–4:45 p.m.

C18 : Measuring and Changing Outcomes in Autoimmune Encephalitis

Location: Salon

1.5

Learning Objectives: Participants should become familiar with the current knowledge of outcomes in autoimmune encephalitis, and recognize limitations in our current practice and measures to improve them.

Moderators:

Sarah F. Wesley, MD, New York, NY

Amy Kunchok, MBBS, Cleveland, OH

Lecture/Faculty:

3:10 p.m.–3:37 p.m.

» Outcome of Autoimmune Encephalitis in Adult and Pediatric Populations

Grace Gombolay, MD, Atlanta, GA

3:37 p.m.–4:04 p.m.

» How To Improve Measurement of Outcomes in Autoimmune Encephalitis

Maarten J. Titulaer, MD, PhD, Rotterdam, Netherlands

4:04 p.m.–4:31 p.m.

» Multidisciplinary Care Models

Justin Abbatemarco, MD, Cleveland, OH

4:31 p.m.–4:38 p.m.

» A Multi-center Exploration of Efficacious Treatment Approaches in LGI1-Ab Encephalitis

John N. Soltys, MD

4:38 p.m.–4:45 p.m.

» Immunotherapy Principles and Biomarkers in Cryptogenic New-Onset Refractory Status Epilepticus (cNORSE)

Soo Hyun Ahn, MD

SATURDAY, JULY 20

3:10 p.m.–4:45 p.m.

C19 : Monitoring Necessities for Immunotherapy Prescribers 1.5

Location: 212-214

Learning Objectives: Participants should be able to mitigate risks of prescribed immunotherapy by appropriate monitoring during these treatments.

Moderators:

Shamik Bhattacharyya, MD, FAAN, Boston, MA

Alison L. Christy, MD, PhD, Portland, OR

Lecture/Faculty:

3:10 p.m.–3:37 p.m.

» Pregnancy, Lactation, and Fertility

Riley Bove, MD, FAAN, Berkeley, CA

3:37 p.m.–4:04 p.m.

» Risk Mitigation on Immunosuppression

Erin Longbrake, MD, PhD, FAAN, New Haven, CT

4:04 p.m.–4:31 p.m.

» Vaccination Strategies and Precautions

Jennifer McCombe, MD, Edmonton, AB, Canada

4:31 p.m.–4:38 p.m.

» Neuroinvasive West Nile Virus Associated with Anti-CD20 Therapies in a University Health System

Rumyar V. Ardakani, MD

4:38 p.m.–4:45 p.m.

» Incidence and Outcome of Meningococcal Infection With Eculizumab or Ravulizumab in Patients With gMG or NMOSD: An Analysis of US Clinical Practice

Shirali Pandya, PhD

4:45 p.m.–5:30 p.m.

C20 : Closing Keynote

Location: Salon

Learning Objectives: Participants should become familiar with the advances in the treatment of paraneoplastic neurological diseases.

Moderators:

John E. Greenlee, MD, FAAN, Salt Lake City, UT

Marinos C. Dalakas, MD, FAAN, Philadelphia, PA

Lecture/Faculty:

4:45 p.m.–5:25 p.m.

» Paraneoplastic Neurological Diseases: What’s Next

Sean J. Pittock, MD, Rochester, MN

5:25 p.m.–5:30 p.m.

» Closing

Stacey Clardy, MD, PhD, FAAN, Salt Lake City, UT

Anastasia Zekeridou, MD, PhD, Rochester, MN

Information is accurate as of June 28, 2024, and is subject to change.

SHOULD YOU SECOND-GUESS THAT MG DIAGNOSIS?

The presence of autonomic symptoms may indicate a different disorder 1,2

Lambert-Eaton myasthenic syndrome (LEMS) is underrecognized and often mistaken for myasthenia gravis (MG).2,3

In fact, more than 1/3 of LEMS patients were previously diagnosed with MG.2

Autonomic symptoms, including dry mouth, orthostatic hypotension, constipation, and impotence, are more common in LEMS and may indicate a missed LEMS diagnosis.1,2

LEMS should be considered in patients diagnosed with MG who have autonomic symptoms or suboptimal response to treatment as well as in patients with small cell lung cancer.1

Catalyst Pharmaceuticals offers no-cost anti-VGCC antibody testing for patients who have symptoms suggestive of LEMS. Scan the code to learn more and request a free test.

References: 1. Vernino S, Morrell D, Shechter G, Grebla R, Rosenfeld J. Diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) may be missed among patients with myasthenia gravis and autonomic dysfunction: results from a US database analysis. Abstract presented at: American Academy of Neurology (AAN) annual meeting. April 13-18, 2024; Denver, CO. 2. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107. 3. Merino-Ramírez MÁ, Bolton CF. Review of the diagnostic challenges of Lambert-Eaton syndrome revealed through three case reports. Can J Neurol Sci. 2016;43(5):635-647.

Pharmaceuticals, Inc.

EXHIBIT HALL MAP

EXHIBITORS

Alexion, AstraZeneca Rare Disease Medical Affairs

Booth 17

alexion.com

Alexion is a global biopharmaceutical company with the mission of transforming the lives of people affected by rare diseases by continuously innovating and creating meaningful value in all that we do. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

Alexion, AstraZeneca Rare Disease

Booth 6

alexion.com

Amgen Rare Disease

Booth 16

amgen.com

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

argenx Medical

Booth 18

argenx.com

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www. argenx.com.

argenx Commercial

Booth 7

argenx.com

ARUP Laboratories

Booth 12

aruplab.com

Neurology testing can be complex. ARUP Laboratories’ trusted experts have crafted tailored laboratory testing solutions, and our targeted tests are made to fit the needs of your patients. As a national nonprofit and academic reference laboratory, our medical experts are committed to continually improving our test menu to provide accurate, reliable results.

Cartesian Therapeutics

Booth 5

cartesiantherapuetics.com

Cartesian Therapeutics is a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases. Leveraging its proprietary RNA Armory® platform, Cartesian’s internally manufactured portfolio is designed to be administered in an outpatient setting without preconditioning chemotherapy. The Company’s lead asset is Descartes-08, an autologous BCMA-directed mRNA CAR-T for autoimmune disease which recently received the US FDA’s RMAT designation for gMG.

Catalyst Pharmaceuticals

Booth 13

catalystpharma.com

Catalyst is committed to developing and commercializing novel medicines for patients living with rare and difficult to treat neurological diseases.

Immunovant, Inc.

Booth 20

immunovant.com

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.

Mayo Clinic Laboratories

Booth 15

mayocliniclabs.com

TESTING DEVELOPED BY NEUROLOGISTS, FOR NEUROLOGISTS Through our integration with Mayo Clinic, Mayo Clinic Laboratories leads the industry in turning test results into clinical answers. Neurology testing is rapidly evolving, with increasing numbers of clinically relevant biomarkers discovered each year. Mayo Clinic Laboratories collaborates closely with the practice and is designed to offer the most complex, clinically validated testing. Our disease experts support health care professionals in test selection and results interpretation to ensure proper test utilization and the highest quality of care.

Medeia- Brainview

Booth 10

brainview.com

BrainView helps clinicians with objective data on a patient’s core brain functions like: memory, attention, information processing, and executive function. BrainView can identify symptoms of cognitive dysfunction such as fatigue, memory loss or brain fog, in some cases several years before they manifest.

EXHIBITORS

MedTech International Group

Booth 1

medtechinternationalgroup.com

Med-Tech International is a mission-driven company. For us, that means a strong collaboration with our clinical partners to continuously deliver innovative and alternative therapies to fulfill clinical needs and improve patient outcomes.

Morris & Dickson

Booth 21

morrisdickson.com

Morris & Dickson (M&D) is the industry’s largest independently owned full-line and specialty pharmaceutical distributor, with a proud heritage of putting pharmacies and patients first. M&D’s hallmark is an unmatched combination of savings, services, support, and innovation. M&D services retail pharmacies, health systems, surgery centers, and clinics in 27 states nationally - and growing.

Myasthenia Gravis Holistic Society

Booth 19

mgholisticsociety.org

The MG Holistic Society is a non-profit organization dedicated to improving the quality of life for individuals with Myasthenia Gravis (MG). Emphasizing a holistic approach, the society offers comprehensive support through advocacy, education, and wellness programs. The organization focuses on integrating healthy lifestyle practices, spiritual balance, and mental wellness into the daily lives of those affected by MG. With a diverse team of volunteers and professionals, the society addresses healthcare disparities and promotes overall wellness within the MG community. For more information, visit http://www.mgholisticsociety.org.

OPED Medical

Booth 4

o-dhs.com

OPED is a German based company with over 30 years experience in the orthosis world. We have formed a team to create our own AI technology and offer a Full Gait Analysis in less than 3 minutes.

Piedmont Healthcare

Booth 9

piedmont.org

Piedmont Healthcare is a top-rated system with award winning hospitals and employees comprised of 23 hospitals, more than 2,500 physicians, and over 700 clinic practice locations across greater Atlanta and North Georgia. With over 1 million outpatient encounters, you will have the opportunity to see and treat a variety of medical conditions. Metro Atlanta’s vibrant economy fuels a wealth of global communities and diverse cultural experiences, while the state of Georgia offers coastline beaches and mountain views. Live and work with the best at Piedmont in the big and small towns of the Peach State. www.piedmont.org/practicewithus

Prosper Infusion

Booth 2

prosperinfusion.com

Designed from the ground up, Prosper Infusion re-imagines infusion care for patients with chronic, complex diseases. We promise to put our best foot forward in ensuring each patient receives high-quality healthcare that promotes improved health outcomes and efficiency. That means not just focusing on your infusion care, but helping you be healthy all-around.

SamaCare

Booth 14

samacare.com

SamaCare is one place to submit, track and manage all prior authorizations across all payers and drugs.

Sutter Health

Booth 3

sutterhealth.org

Sutter Health is a not-for-profit health system that delivers top-rated personalized care in more than 100 Northern California communities. It has recently been among the Top 15 Health Systems in the nation by Truven Health Analytics. As a not-for-profit, Sutter Health invests its earnings back into the communities it serves.

Takeda Pharmaceuticals

Booth 8

takeda.com

Takeda Neuroscience is driven by the unmet needs of patients with rare neurological diseases. Our mission is to bring innovative and potentially disease-modifying medicines to these patients. To deliver on this mission, our approach leverages advances in molecularly and genetically defined targets, biomarkers, and targeted modalities. Our commitment to patients is focused on our goal of developing new treatments for those who need them most.

UCB, Inc

Booth 22

ucb.com

UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. Follow us on Twitter: @UCB_news.

Wellstar Health Systems

Booth 11

wellstar.org

Wellstar Health Systems is one of the largest and one of the more integrated healthcare systems in Georgia. Nationally ranked and locally recognized for our high-quality care inclusive culture and exceptional doctors. As a not-for profit health system, our passion for people extends beyond our system and into the communities we serve. Across Wellstar Health System, our board-certified neurologists rely on world-class training and decades of combined experience to meet your patients’ complete neurological needs.